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Abstract
Background: Oral food challenge using gluten and cofactors is the gold standard to
diagnose wheat‐dependent exercise‐induced anaphylaxis (WDEIA), but this pro-
cedure puts patients at risk of an anaphylactic reaction. Specific IgE to ω5‐gliadins
as major allergens and skin prick tests to wheat may yield negative results. Thus, we
designed a proof‐of‐principle study to investigate the utility of the basophil acti-
vation test (BAT) for WDEIA diagnosis.
Methods: Different gluten protein types (GPT; α‐, γ‐, ω1,2‐ and ω5‐gliadins, high‐
molecular‐weight glutenin subunits [HMW‐GS] and low‐molecular‐weight glutenin
subunits [LMW‐GS]) and gluten were used in different concentrations to measure
basophil activation in 12 challenge‐confirmed WDEIA patients and 10 control
subjects. The results were compared to routine allergy diagnostics. Parameters
analyzed include the percentage of CD63+ basophils, the ratio of %CD63+ basophils
induced by GPT/gluten to %CD63+ basophils induced by anti‐FcεRI antibody, area
under the dose‐response curve and test sensitivity and specificity.
Results: GPT and gluten induced strong basophil activation for %CD63+ basophils
and for %CD63+/anti‐FcɛRI ratio in a dose‐dependent manner in patients, but not in
controls (p < 0.001, respectively). BAT performance differed from acceptable (0.73
for LMW‐GS) to excellent (0.91 for ω5‐gliadins) depending on the specific GPT as
evaluated by the area under the receiver operating characteristic curve. Patients
showed individual sensitization profiles. After determination of the best cut‐off
points, ω5‐gliadins and HMW‐GS showed the best discrimination between pa-
tients and controls with a sensitivity/specificity of 100/70 and 75/100, respectively.
Conclusion: This study shows the alternative role of BAT in better defining WDEIA
and the causative wheat allergens. The best BAT parameters to distinguish
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WDEIA patients from controls were %CD63+ basophil values for ω5‐gliadins and
HMW‐GS.
K E YWORD S
ω5‐gliadin, basophil activation test, gluten, wheat allergy, wheat‐dependent exercise‐induced
anaphylaxis (WDEIA)
1 | INTRODUCTION
Wheat‐dependent exercise‐induced anaphylaxis (WDEIA) is a rare,
but potentially life‐threatening cofactor‐induced wheat allergy. ω5‐
gliadins and high‐molecular‐weight glutenin subunits (HMW‐GS) are
most often reported as major allergens, but reactions to other gluten
protein types (GPTs) from wheat, like low‐molecular‐weight glutenin
subunits (LMW‐GS), α‐ and γ‐gliadins were also described. All GPT
together constitute gluten, the storage proteins in wheat flour.1‐4
WDEIA diagnosis is challenging, because of the variety of
possible allergenic wheat proteins and the combination with a
cofactor. Skin prick tests (SPTs) and specific IgE (sIgE) to wheat may
be negative. Even sIgE to ω5‐gliadins are only positive in about 80%
of WDEIA patients, indicating that other GPT also play a role in
WDEIA. Wheat product and exercise challenge failed to induce
symptoms in the majority of patients despite a clear history.1,4,5
Thus, oral food challenge with gluten, that has a protein content of
70%–80% compared to the 8%–15% in wheat flour, combined with
cofactors is often needed to overcome non‐responsiveness.6,7
A new approach to complement WDEIA diagnosis is the basophil
activation test (BAT) combined with florescence‐activated cell sort-
ing. Stimulation with an allergen‐containing solution (allergen test
solution [ATS]) induces upregulation of the expression of cell surface
proteins, such as CD63 or CD203c. BAT‐derived parameters such as
the percentage of basophils that respond to a given dose of the ATS
or the area under the curve (AUC) of a dose‐response curve have
been shown to be sensitive biomarkers corresponding to the clinical
severity of anaphylactic reactions.8,9 The BAT has been established
for the identification of different immediate allergies, like allergy
against wheat,8,10 hymenoptera venom,11 and alpha‐galactose.12
The aim of this proof‐of‐principle study was to investigate the
utility of the BAT to improve WDEIA diagnosis and to determine
individual sensitization profiles in WDEIA patients to different iso-
lated and well‐characterized GPT and gluten.
2 | METHODS
2.1 | Study population
The following exclusion criteria were considered in the selection of
participants to avoid potential confounding factors and/or health risk
to any of the participants: Pregnancy/lactation; systemic intake of
corticosteroids (cortisone) 3 weeks and/or antihistamines (anti‐
pruritic drugs) 1 week before the start of the test; intake of laxatives,
anti‐diarrhea drugs, thyroid hormone preparations, antibiotics,
immunosuppressive drugs, analgesic drugs (aspirin, NSAIDs, etc.)
taking psychotropic drugs and certain blood pressure medications
(ACE inhibitors, ß‐blockers); serious internal diseases (gastrointes-
tinal, neurological, cardiovascular, rheumatic diseases, celiac disease,
cancer, kidney diseases, acute infections, etc.); bronchial asthma.
A total of 23 participants were consecutively recruited from the
medical center (15 f, 8 m, 25–76 years). Twelve of them were pa-
tients with a history of WDEIA based on positive oral food challenge,
SPT, sIgE, and clinical history (5 f, 7 m, 26–60 years, Table 1).
Provocations had been done with 8–32 g gluten intake as
described.7,13 Some patients, depending on their history, were given
increasing doses of cofactors (500–1000 mg of ASA ± 10–20 ml of
95% ethanol; Braun, Melsungen, Germany diluted with 200 ml of
black currant‐flavored water) 30 min before gluten challenge
and standardized aerobic and anaerobic exercise was undertaken
30–60 min after gluten ingestion. Eleven individuals without a history
of any wheat‐related disorder were included in the study as controls
(10 f, 1 m, 25–76 years, Table 2).
The study protocol was approved by the ethics committee of the
Technical University of Munich and all participants gave written
informed consent before being included in the study.
2.2 | Skin prick test
SPT was carried out on the forearm with the following substan-
ces: wheat flour, gluten, isolated LMW‐GS, HMW‐GS, and gliadins.
A 10% histamine‐dihydrochloride solution (ALK‐Abello, Hørsholm,
Denmark) was used as positive and isotonic sodium chloride solution
(Fresenius Kabi Deutschland GmbH) as negative control.7 Details of
the production and characterization of GPT can be found in the Sup-
porting Methods.
2.3 | Serum sIgE and total IgE
Serum sIgE and total IgE levels were measured by ImmunoCap and
Phadia 250 (Thermo Fisher Scientific). Serum sIgE levels of the
following allergens were determined: Dermatophagoides pteronyssinus
(d1), timothy grass (g6), birch pollen allergen (Bet v 1, t215), wheat
flour (f4), rye flour (f5), gluten (f79), gliadin (f98), ω5‐gliadin (Tri a 19,
f416), and lipid‐transfer protein (Tri a14, f433).
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2.4 | Preparation of BAT ATSs
Gliadins were extracted from wheat gluten using 60% aqueous
ethanol. After dialysis and lyophilization, the gliadin fraction was
separated into ω5‐, ω1,2‐, α‐, and γ‐gliadins by preparative reversed‐
phase high‐performance liquid‐chromatography. The glutenins were
extracted from the residue after gliadin removal using 50% aqueous
propanol, 60°C and reducing conditions. The HMW‐GS and LMW‐GS
were obtained by sequential precipitation with 40% and 80%
acetone, respectively.14‐16 Details of the production and character-
ization of the GPT can be found in the Supporting Methods.
GPT or gluten (15 mg) and 0.6 ml pepsin solution (0.6 mg/ml
pepsin solved in 0.01 mol/L hydrochloric acid, enzyme‐substrate ratio
of 1/25) were incubated for 120 min at 37°C. The digest was stopped
by adjusting the pH value to 7.0 with sodium hydrogen carbonate
solution (50 mg/ml). The solution was filtered (0.45 μm) and the
protein/peptide concentrations were measured at 205 nm by a micro
volume UV/VIS spectrophotometer NanoDrop One (Thermo Fisher
Scientific). If necessary, the sample solution was diluted with water to
a concentration of 4 mg/ml. Further dilutions were made, to receive
the following concentrations: 2.0, 0.8, 0.4, and 0.08 mg/ml. A pepsin‐
control was prepared in the same way, but without gluten proteins.
ATS were prepared and stored at −20°C in aliquots until use in BAT.
2.5 | Basophil activation test
For quantitative determination of in vitro basophil activation, Flow
CAST (Buehlmann Laboratories AG) was used, as described previ-
ously.12 Venous blood was collected from participants in EDTA tubes
and used immediately. The blood samples were gently homogenized at
room temperature (RT). Per measurement, 50 μl of ATS (concentra-
tion 4.0–0.2 mg/ml), 100 μl stimulation buffer, 50 μl blood and 20 μl
staining reagent were gently mixed by hand in polystyrene tubes. The
staining reagent consisted of anti‐CD63‐fluorescein‐isothiocyanate
and anti‐CCR3‐pycoerythrin monoclonal antibodies (mAb). The
tubes were then incubated for 25min at 37°C. By addition of 2ml lysis
reagent and standing for 5 min in the dark at RT, the stimulation was
stopped. The tubes were centrifuged at 500 � g for 5 min. The su-
pernatant was decanted and the residue was resuspended in 200 μl of
wash buffer by gentle mixing. Highly specific anti‐FcεRI mAb and N‐
formyl‐methionyl‐leucyl‐phenylalanine were used as positive con-
trols. To determine the background value, stimulation buffer alone
was used. The flow cytometric analysis was performed using a
FACSCalibur system (Becton‐Dickinson Immunocytometry System)
with a 488 nm, 15 mW and a 635 nm, 10 mW argon laser. Basophils
were gated as low side scatter CCR3/side scatterlow. CCR3 was used
to identify basophils and CD63 as basophil activation marker, both
marked with fluorescence‐dye‐labeled mAb. BD CellQuest (Becton‐
Dickinson Immunocytometry System) was used for data analysis. In
each measurement, ≥450 basophil granulocytes (BG) were counted.
The upregulation of the basophil activation marker CD63 by the
tested ATS reflects the induced basophil activation.11,12,17,18
2.6 | Determination of different BAT parameters
The basophil activation (%CD63+ basophils) was calculated by the
percentage of CD63‐expressing BG relative to the total number of
counted BG in each measurement. The %CD63+ basophils/anti‐FcεRI
ratio is defined as the quotient of the maximum percentage of acti-
vated %CD63+ basophils, induced by an IgE‐dependent stimulus, and
the percentage of activated basophils triggered by the anti‐FcεRI
mAb as positive control.
2.7 | Statistical analysis
Statistical analysis was performed with SigmaPlot 14 (Systat Soft-
ware GmbH) and Origin 19 (OriginLab Corporation). Statistical sig-
nificance was tested by one‐way ANOVA and Dunn's post hoc test.
Receiver operating characteristic (ROC) analyses were carried out to
estimate the discriminatory ability of the investigated parameters.
Therefore, the area under the ROC curve, was used as further
characteristic. The optimized cut‐off of basophil activation (%) for
best selectivity and specificity was determined from the ROC
curve. Correlations between BAT results (maximum %CD63+ baso-
phils, %CD63+/FcεRI ratio), diameter of wheals and erythema in SPT,
severity (grouped comparisons I, II, III) and sIgE values were analyzed
using Spearman's correlation test.
3 | RESULTS
3.1 | Study population
Twelve patients (7 m, 5 f; age range: 26–60 years; median age:
48 years) with a clinical history of WDEIA and positive challenge test
were included in the study (Table 1). The control population con-
sisted of 11 controls without a clinical history of any wheat‐related
disorder; six subjects were atopic. One subject with atopy was
excluded, because of non‐responsiveness to the positive control anti‐
FcɛRI mAb in the BAT. Therefore, 10 controls were analyzed
further (1 m, 9 f; age range: 25–76 years; median age: 44 years)
(Table 2).
3.2 | SPT, serum sIgE and total IgE
A SPT is classified as positive when the diameter of the wheal, caused
by the test substance, is greater or equal than the diameter of the
wheal of the negative control with 3 mm added. Patients did not
show wheals for the negative control, and they all showed a distinct
allergic reaction to the positive control. There were positive re-
sponses to gluten and gliadins in SPT in all patients (Table 3,
Figure 1). In case of wheat flour, HMW‐GS and LMW‐GS positive
results were obtained with only two exceptions. Patients p7 and p12
were the only ones showing negative results to some of the test
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substances (p7: wheat flour, p12: wheat flour, LMW‐GS, HMW‐GS).
There were no significant differences in wheal or erythema diameter
between wheat flour, gluten, gliadins, HMW‐GS, and LMW‐GS be-
tween the patients (p > 0.05).
Significantly higher values were found for total IgE and sIgE
against Dermatophagoides pteronyssinus, timothy grass, wheat flour,
rye flour, gluten gliadins, and ω5‐gliadins in patients compared to
controls (p < 0.05), respectively. No significant differences between
TAB L E 2 Characteristics of controls: sex, age, atopic dermatitis, total IgE (KU/L), sIgE (KU/L) against wheat flour, rye flour, gluten,
gliadins, ω5‐gliadin, lipid‐transfer protein, dermatophagoides pteronyssinus, timothy grass, birch pollen allergen
Controls Sex Age AD Total IgE
sIgE
WF RF G Glia ω5 Tri a 14 DP TG Bet v1
1 F 76 ‐ 82.7 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10
2 F 71 RCA, OAS 38.9 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 15.9
3 F 27 RCA, OAS 44.2 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 6.16 5.30
4 F 26 ‐ 6.7 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10
5 F 25 ‐ 5.7 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10
6 F 32 RCA, A 49.8 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 2.62 0.86 1.72
7 F 26 ‐ 15.0 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10
8 F 51 ‐ 3.5 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10
9 M 54 RCA 28.0 <0.10 <0.10 <0.10 <0.10 <0.10 <0.10 2.87 1.86 <0.10
10 F 55 RCA 960.0 1.95 1.68 0.19 <0.10 <0.10 <0.10 0.33 2.36 >100
Abbreviations: A, asthma; AE, atopic eczema; AD, atopic disease; Bet v1, birch pollen allergen; DP, dermatophagoides pteronyssinus; G, gluten; Glia,
gliadins; OAS, oral allergy syndrome; RCA, allergic rhinoconjuctivitis; RF, rye flour; sIgE, specific immunoglobulins; TG, timothy grass; Tri a 14, lipid‐
transfer protein; ω5, ω5‐gliadin; WF, wheat flour.
TAB L E 3 Skin prick test results for WDEIA patients (p) to wheat flour, gluten, gliadins and HMW‐GS/LMW‐GS
Patients
Wheat flour Gluten Gliadins LMW‐GS HMW‐GS Histamine NaCl
W E W E W E W E W E W E W E
1 4.0 13.0 6.5 14.0 7.0 18.0 4.5 9.0 4.5 11.0 6.0 8.0 0.0 0.0
2 10.5 15.0 9.0 15.0 7.0 10.0 9.0 16.0 12.5 18.0 6.0 9.0 0.0 2.0
3 6.5 9.0 6.0 17.0 7.0 15.0 7.5 18.0 7.0 17.0 7.0 10.0 0.0 0.0
4 6.0 7.0 7.0 10.0 7.0 8.0 10.0 15.0 10.0 13.0 6.0 8.0 0.0 0.0
5 6.0 9.0 4.0 14.0 4.0 5.0 7.0 20.0 5.0 20.0 6.0 8.0 0.0 2.0
6 6.0 15.0 6.0 14.0 4.5 14.0 9.0 23.0 7.0 19.0 6.0 13.0 0.0 0.0
7 2.5 5.0 5.5 11.0 3.0 5.0 4.5 9.0 5.5 8.0 6.0 11.0 0.0 0.0
8 7.0 18.0 12.0 31.0 8.5 24.0 12.0 24.0 6.0 17.0 6.0 19.0 0.0 2.0
9 5.0 18.0 3.5 10.0 7.5 15.0 3.0 9.0 5.0 16.0 6.0 21.0 0.0 0.0
10 5.5 22.0 4.4 21.0 5.0 23.0 5.5 25.0 5.5 22.0 4.0 15.0 0.0 0.0
11 8.0 18.0 6.5 21.0 12.0 27.0 11.0 28.0 8.5 25.0 6.0 21.0 0.0 2.0
12 1.0 2.0 3.0 7.0 3.5 6.0 1.5 2.0 2.5 4.0 5.0 18.0 0.0 1.0
Range 1.0–12.02.0–25.03.0–15.05.0–35.0 3.0–11.0 5.0–32.0 1.0–18.01.0–30.0 2.0–13.0 3.0–30.0 3.0–7.0 7.0–30.0 ‐ 0.0–2.0
Median 5.8 12.6 6.1 15.4 6.3 14.2 7.0 16.5 6.6 15.8 5.8 13.4 0.0 0.8
Note: The results are the median of a double determination n = 2 (except WDEIA patient 4, n = 1). Isotonic sodium chloride was used as negative (NaCl)
and a 10% histamine solution as positive control (histamine). The diameters for wheals and erythema were documented in mm. A result is classified as
positive (marked in bold), when the diameter of the wheal, caused by a test substance, is greater or equal than the diameter of the wheal caused by the
negative control with 3 mm added. The range and median of all patients' results per test substance is documented.
Abbreviations: E, erythema; HMW, high‐molecular weight glutenin subunits; LMW‐GS, low‐molecular weight glutenin subunits; W, wheals; WDEIA,
wheat‐dependent exercise‐induced anaphylaxis.
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F I GUR E 1 Exemplary skin prick test (SPT) results for wheat‐dependent exercise‐induced anaphylaxis patient 3. The following
SPT substances were applied: +: histamine positive control, −: sodium chloride negative control, 1: gluten, 2: strongly hydrolyzed
wheat protein, 3: slightly hydrolyzed wheat protein, 4: low‐molecular‐weight glutenin subunits, 5: high‐molecular‐weight glutenin
subunits, 6: gliadins, 7: special gluten sample (significantly lower ω5‐gliadin content), 8: wheat flour
patients and controls were found for sIgE against birch pollen
allergen (Bet v 1) and lipid‐transfer protein (Tri a14) (p > 0.05). For
details see Tables 1 and 2.
3.3 | Evaluation of the response induced by ATSs in
BAT
The induced allergenic response to the ATS was evaluated by three
parameters used in BAT: %CD63+ basophils, %CD63+/anti‐FcɛRI
ratio and AUC of dose‐response curves. The ATS made from gluten
and GPT induced basophil activations in patients with WDEIA.
The basophil activation was dose‐dependent up to a maximum of
71.3 %CD63+ basophils in case of ω5‐gliadins, 61.5% for gluten,
59.8% for LMW‐GS, 53.7% for γ‐gliadins, 50.7% for HMW‐GS,
49.2% for α‐gliadins, and 37.3% for ω1,2‐gliadins. Significant dif-
ferences between patients and controls were found for each ATS
at every concentration tested (p < 0.001) (Figure 2). There were
no significant differences in the background values for patients
(range: 0.4%–1.7% CD63+ basophils, median: 0.9% CD63+ baso-
phils) and controls (range: 0.4%–3.1% CD63+ basophils, median:
1.1% CD63+ basophils). The %CD63+/anti‐FcɛRI ratio was signifi-
cantly higher for gluten and all GPT for patients compared with
controls at most concentrations (p < 0.001) (Figure S1). The dose‐
response curves were generated from the values of %CD63+
basophils. The AUC as evaluation parameter combines the trig-
gered allergic response (%CD63+ basophils) and all tested doses in
one. The AUC of ω5‐gliadins, α‐gliadins, and HMW‐GS were
significantly higher in patients compared to controls (p < 0.001),
but there were no significant differences for ω1,2‐gliadins, γ‐glia-
dins, LMW‐GS, and gluten (p > 0.05). For patients, median AUC
values were 56.5 (range: 3.8–232.2) for ω5‐gliadins, 34.7 (range:
0.4–163.7) for α‐gliadins, and 24.0 (range: 3.7–102.9) for HMW‐
GS. Table 4 shows the AUCs of dose‐response curves of gluten
and GPT for patients and controls.
3.4 | ROC curves
The ROC curve describes how accurately the test can distinguish
patients from controls. The greatest AUC values for concentration‐
independent ROC curves were determined for %CD63+ basophils
as characteristic, for ω5‐gliadins (0.908), HMW‐GS (0.867), and
gluten (0.850) (Table 5; Figure 3). Concentration‐independent ROC
curves were generated from the maximum values for %CD63+ ba-
sophils out of all tested concentrations for each single ATS in pa-
tients and controls. The optimal discrimination threshold (cut‐off) for
%CD63+ basophils, when a basophil activation is classified as
“allergen response” to a ATS, was determined for best sensitivity and
specificity of concentration‐independent ROC curves (Table 5).
Concentration‐dependent ROC curves showed best results at
4.00 mg/ml for ω5‐gliadins and HMW‐GS, 2.00 mg/ml for LMW‐GS
and gluten as well as 0.8 mg/ml for ω1,2‐, α‐ and γ‐gliadins. More
information about ROC curves and results for concentration‐
dependent ROC curves are presented in the Supporting Informa-
tion (Tables S1 and S2; Figure S2).
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4 | DISCUSSION
In this proof‐of‐principle studywe show that BATwith gluten andGPT
solutions is a very promising tool to better define WDEIA. Gluten and
GPT induced strong basophil activation in a dose‐dependentmanner in
patients at most allergen concentrations, but not in controls. This is
important, because the necessity of challenge tests together with one
or several cofactors makes the diagnosis of WDEIA challenging. SPT
and sIgE are routine diagnostic measures to detect sensitization, but
SPT and sIgE to wheat flour extracts and even sIgE toω5‐gliadins may
give negative results in WDEIA. Alternative in vitro methods to
confirm the diagnosis are needed.7
Our results are in agreement with a study by Chinuki et al. who
measured basophil CD203c expression to differentiate between
classical WDEIA with IgE primarily directed against ω5‐gliadins and a
new WDEIA subtype caused by hydrolyzed wheat protein (HWP_A)
F I GUR E 2 Dose‐dependent basophil activation (%CD63+ basophils) in wheat‐dependent exercise‐induced anaphylaxis patients (blue) and
controls (white) using allergen test solutions from gluten protein types ω5‐gliadins (A), ω1,2‐gliadins (B), α‐gliadins (C) and γ‐gliadins (D), high‐
molecular‐weight glutenin subunits (E) and low‐molecular‐weight glutenin subunits (F), and gluten (G) at concentrations of 4.0, 2.0, 0.8, 0.4,
and 0.08 mg/ml and the positive controls anti‐FcɛRI monoclonal antibody and N‐formyl‐methionine‐leucyl‐phenylalanine (fMLP). Significant
differences between patients and controls are indicated by asterisks (one‐way ANOVA, Dunn's post hoc test, p < 0.001). Diamonds indicate
individual outliers beyond the interquartile range
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TAB L E 4 Area under the dose‐response curve (%CD63+ basophils by concentration of the allergen test solutions [mg/ml]) from patients
and controls for gluten and ω5‐, ω1,2‐, α‐, and γ‐gliadins and HMW‐GS/LMW‐GS
Gluten ω5‐gliadins ω1,2‐gliadins α‐gliadins γ‐gliadins HMW‐GS LMW‐GS
p1 44.4 114.2 44.0 54.4 10.6 28.0 46.9
p2 12.6 4.9 24.9 39.4 18.7 35.2 41.1
p3 2.8 3.8 4.2 7.9 7.3 17.2 40.7
p4 5.4 7.0 6.6 8.4 9.0 19.0 20.5
p5 2.8 6.5 2.6 2.6 3.7 3.7 3.1
p6 44.8 80.8 48.7 63.8 49.0 49.7 80.7
p7 1.7 6.5 3.0 0.4 0.8 0.9 2.3
p8 3.0 44.3 1.1 1.9 3.3 1.3 0.5
p9 170.4 232.2 108.1 163.7 156.2 102.9 172.1
p10 9.4 50.7 3.1 3.7 4.0 8.4 4.3
p11 9.8 67.2 12.4 11.8 7.9 8.7 9.3
p12 7.5 59.8 56.6 58.1 29.9 12.9 24.6
Range (p) 1.7–170.4 3.8–232.2 1.1–108.1 0.4–163.7 0.8–156.2 0.9–102.9 0.5–172.1
Median (p) 26.2 56.5 26.3 34.7 25.0 24.0 37.2
c1 3.6 3.8 2.1 1.3 2.5 1.7 2.4
c2 3.8 3.3 1.5 6.9 8.1 1.9 6.5
c3 6.3 3.8 5.9 6.2 6.6 8.4 6.7
c4 4.4 4.2 4.7 4.4 5.0 7.2 5.2
c5 2.1 2.2 3.4 1.4 3.0 4.1 3.8
c6 9.8 16.3 9.9 8.3 11.2 7.4 9.4
c7 3.3 3.9 5.4 3.7 5.0 4.4 6.3
c8 1.6 2.7 2.3 2.2 3.5 0.6 1.5
c9 3.1 18.3 2.8 1.8 5.8 4.6 3.7
c10 1.4 2.0 3.3 1.5 1.2 1.5 1.6
Range (c) 1.4–9.8 2.0–18.3 1.5–9.9 1.3–8.3 1.2–11.2 0.6–8.4 1.5–9.4
Median (p) 3.9 6.1 4.1 3.8 5.2 4.2 4.7
Abbreviations: c, control; HMW‐GS, high‐molecular‐weight glutenin subunits; LMW‐GS, low‐molecular‐weight glutenin subunits; p, patient.
TAB L E 5 Patient and control data
from concentration‐independent ROC
curves for ATSs from gluten and ω5‐,
ω1,2‐, α‐, and γ‐gliadins and HMW‐GS/
LMW‐GS with AUC and optimal
discrimination threshold for %CD63+
basophils (cut‐off), when a basophil
activation is classified as “allergen
response” to an ATS
ATS AUC Cut‐off (%CD63+ basophils) Sensitivity (%) Specificity (%)
ω5‐gliadins 0.908 1.8 100 70
HMW‐GS 0.867 3.0 75 100
Gluten 0.850 2.8 75 90
α‐gliadins 0.792 3.4 67 90
ω1,2‐gliadins 0.758 2.6 67 80
γ‐gliadins 0.750 3.1 67 80
LMW‐GS 0.725 2.0 75 70
Abbreviations: ATS, allergen test solutions; AUC, area under the ROC curve; HMW‐GS, high‐
molecular weight‐glutenin subunits; LMW‐GS, low‐molecular‐weight glutenin subunits; ROC,
receiver operating characteristic.
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present in a soap in Japan. Significant enhancement of CD203c
expression was observed with ω5‐gliadins in patients with classical
WDEIA and with HWP_A in patients sensitized by the soap, but not
vice versa.10 However, this study is of limited value for clinical
routine, as (1) they only tested five patients in each group, but no
controls, (2) used only ω5‐gliadins and HWP_A, and (3) measured
CD203c, a different basophil activation marker.
CD63 and CD203c are both in use as activation markers in BAT,
while CD63 is the most common one. The upregulation of CD63 is
closely associated with basophil degranulation induced by allergen
stimuli.19 Hoffmann et al. (2016) reported that the upregulation of
CD203c also occurs to non‐degranulation stimuli, which is not the
case for CD63.20 Eberlein et al. (2015) recommended the combina-
tion of CCR3 as identification marker for basophils and CD63 as
activation marker for basophils in BAT and this is the setup also used
in the present study.21
In BAT, only water‐soluble allergen solutions can be tested in
patient's blood. Chinuki et al. used aqueous, ethanolic, and alkaline
extractions to generate ATS for BAT, but without further protein
characterization.22
In the present study, a well‐characterized representative gluten
sample was used to isolate single GPT, α‐, γ‐, ω1,2‐, and ω5‐gliadins
as well as HMW‐ and LMW‐GS. Detailed information about the
basophil activation in patients to GPT were obtained.23 The challenge
of poor solubility of gluten proteins in aqueous solutions was over-
come by increasing their solubility and accessibility via partial hy-
drolysis with pepsin.24
The highly specific anti‐FcεRI mAb that imitates bridging of the
receptor by an allergen has been used as a positive control in BAT
for numerous years. Rubio et al. analyzed %CD63+ basophils and the
%CD63+/anti‐FcεRI ratio after incubation with milk protein for pre-
diction of the outcome of an oral challenge test. They reported a
significant correlation between the %CD63+/anti‐FcεRI ratio and the
outcome of the oral challenge test, depending on the ingested dose
and reaction severity in patients with food allergy.25
In addition, Santos et al. found a correlation between the
%CD63+/anti‐FcεRI ratio and the reaction severity during oral food
challenge to peanuts.26 In disagreement, there were no correlations
between BAT results (maximum %CD63+ basophils, %CD63+/anti‐
FcεRI ratio), diameter of wheals and erythema in SPT, severity of
symptoms (grouped comparisons I, II, III) and sIgE values (Spearman
correlation test, p > 0.05) in our study.
Basophil activation (%CD63+ basophils) and %CD63+/anti‐FcεRI
ratio were significantly higher in patients for all tested GPT and
gluten in most concentrations compared to controls. Additionally, a
helpful characteristic is the AUC of the dose‐response curve, which
combines basophil activation and sensitivity. In our study, the AUC of
dose‐response curves of ω5‐ and α‐gliadins and HMW‐GS were
significantly higher in patients compared to controls.
Calculating the AUC of ROC curves gives information about the
discriminability of patients from controls depending on different
parameters. BAT performance differed between GPT and gluten,
with only acceptable results for α‐gliadins, γ‐gliadins, LMW‐GS, and
ω1,2‐gliadins, but excellent results for ω5‐gliadins (AUC ROC:
0.908), HMW‐GS (AUC ROC: 0.867) and gluten (AUC ROC: 0.850).
Sensitivity and specificity of basophil activation to these substances
at optimal cut‐off in WDEIA patients as compared to atopic and
nonatopic control subjects were good for ω5‐gliadins (sensitivity:
100%, specificity: 70%), HMW‐GS (sensitivity: 75%, specificity:
100%), and gluten (sensitivity: 75%, specificity: 90%) respectively.
The maximum %CD63+ basophils turned out to be the best param-
eter to differentiate between patients and controls, with significant
differences for all tested allergens. It is conspicuous that sensitivity
and specificity were higher for ω5‐gliadins, HMW‐GS and gluten than
for ω1,2‐, α‐, and γ‐gliadins, and LMW‐GS, because ω5‐gliadins and
HMW‐GS have previously been identified as most relevant allergens
in patients with WDEIA.1‐4
Matsuo et al. recommended to determine sIgE against epitopes
of ω5‐gliadins and HMW‐GS in combination for WDEIA diagnosis.27
Based on our results, we can also confirm this recommendation for
their use in BAT. Other allergenic GPT were less important in our
study.2,4 BAT identified the sensitization profile of WDEIA patients to
be particularly directed against ω5‐gliadins and HMW‐GS, but in
individual patients also against α‐gliadins, γ‐gliadins, LMW‐GS, and
ω1,2‐gliadins. For example, two patients (p6, p9) showed high re-
sponses to LMW‐GS 59.8 (p9) and 31.8 (p6) %CD63+ basophils,
concentration 4.0 mg/ml).1‐4
One limitation of our study is the comparatively small number of
WDEIA patients and controls. Due to the very low prevalence of
F I GUR E 3 Concentration‐independent receiver operating
characteristic curves for ω5‐gliadins, high‐molecular‐weight
glutenin subunits (HMW‐GS), and gluten, which had the highest
sensitivity and specificity. The maximum basophil activation
%CD63+ basophils out of all tested concentrations for each single
allergen test solution in patients and controls was taken to
generate ROC curves
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WDEIA overall, a single‐center study such as ours can only include a
certain number of individuals from the surrounding area. Our main
intent was to identify the most suitable ATS for use in BAT from the
panel of different gluten and GPT preparations tested. Now that we
have identified ω5‐gliadins, HMW‐GS and gluten as most promising
ATS, further work with more WDEIA patients from multiple centers
is needed to put the cut‐off levels on a broader basis and include
WDEIA patients with negative SPT, WDEIA patients with positive
SPT, but positive challenge only with cofactors as well as individuals
who are sensitized (wheat IgE‐positive), but clinically tolerant as
proven by oral challenge.
According to the results of the proof‐of‐principle studywe showed
the potential of the BAT as alternative to routine SPT and sIgE mea-
surements inWDEIA diagnosis. The BAT turned out to be promising to
study the allergenicity of different GPTs, which becomes only possible
after special preparation to increase water solubility, as required for
BAT. Our findings indicate the use of %CD63+ basophils as best
parameter to discriminate between patients and controls and highlight
the allergenicity particularly ofω5‐gliadins and HMW‐GS for WDEIA.
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